161 related articles for article (PubMed ID: 34977029)
1. The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer.
Wang Y; Yuan X; Li J; Liu Z; Li X; Wang Z; Wei L; Li Y; Wang X
Front Cell Dev Biol; 2021; 9():785796. PubMed ID: 34977029
[TBL] [Abstract][Full Text] [Related]
2. CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.
Zhang K; Hong R; Kaping L; Xu F; Xia W; Qin G; Zheng Q; Lu Q; Zhai Q; Shi Y; Yuan Z; Deng W; Chen M; Wang S
Cancer Lett; 2019 Apr; 447():130-140. PubMed ID: 30677445
[TBL] [Abstract][Full Text] [Related]
3. P110α inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer.
Chen H; Si Y; Wen J; Hu C; Xia E; Wang Y; Wang O
Neoplasia; 2023 Sep; 43():100913. PubMed ID: 37348428
[TBL] [Abstract][Full Text] [Related]
4. Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models.
Long F; He Y; Fu H; Li Y; Bao X; Wang Q; Wang Y; Xie C; Lou L
Cancer Sci; 2019 Apr; 110(4):1420-1430. PubMed ID: 30724426
[TBL] [Abstract][Full Text] [Related]
5. The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer.
Wang C; Deng S; Chen J; Xu X; Hu X; Kong D; Liang G; Yuan X; Li Y; Wang X
Front Oncol; 2021; 11():616443. PubMed ID: 34094901
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
7. Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways.
Su B; Huang T; Jin Y; Yin H; Qiu H; Yuan X
Gastric Cancer; 2021 Mar; 24(2):352-367. PubMed ID: 33030616
[TBL] [Abstract][Full Text] [Related]
8. Pyrotinib combined with CDK4/6 inhibitor in HER2-positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients.
Chen Z; Xu Y; Gong J; Kou F; Zhang M; Tian T; Zhang X; Zhang C; Li J; Li Z; Lai Y; Zou J; Zhu X; Gao J; Shen L
Clin Transl Med; 2020 Aug; 10(4):e148. PubMed ID: 32898333
[TBL] [Abstract][Full Text] [Related]
9. Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2
Bu J; Zhang Y; Niu N; Bi K; Sun L; Qiao X; Wang Y; Zhang Y; Jiang X; Wang D; Ma Q; Li H; Liu C
Elife; 2023 Jan; 12():. PubMed ID: 36602226
[TBL] [Abstract][Full Text] [Related]
10. Pan-HER Tyrosine Kinase Inhibitor Pyrotinib Enhances Radiosensitivity via ERK1/2 Pathway in HER2-Positive Gastric Cancer.
Niu Q; Liu J; Huang T; Su B; Zhang Y; Yuan X
Oncol Res Treat; 2023; 46(1-2):11-25. PubMed ID: 36481773
[TBL] [Abstract][Full Text] [Related]
11. Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors.
Zhang J; Yin G; Ye C; Feng M; Ji C; Zhou W; Wang F; Yu L; Huang S; Yu Z
Chin J Cancer Res; 2024 Apr; 36(2):124-137. PubMed ID: 38751436
[TBL] [Abstract][Full Text] [Related]
12. Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2
Yi J; Chen S; Yi P; Luo J; Fang M; Du Y; Zou L; Fan P
Oncol Res; 2020 Dec; 28(5):519-531. PubMed ID: 32727638
[TBL] [Abstract][Full Text] [Related]
13. Pyrotinib and chrysin synergistically potentiate autophagy in HER2-positive breast cancer.
Liu X; Zhang X; Shao Z; Zhong X; Ding X; Wu L; Chen J; He P; Cheng Y; Zhu K; Zheng D; Jing J; Luo T
Signal Transduct Target Ther; 2023 Dec; 8(1):463. PubMed ID: 38110365
[TBL] [Abstract][Full Text] [Related]
14. Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report.
Xie N; Liu L; Tian C; Hu Z; Ouyang Q
Ann Transl Med; 2021 Aug; 9(16):1356. PubMed ID: 34532493
[TBL] [Abstract][Full Text] [Related]
15. Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib.
Lian X; Zhu C; Lin H; Gao Z; Li G; Zhang N; Cao B; Kang Y
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32022229
[TBL] [Abstract][Full Text] [Related]
16. Significant response to the combination of pyrotinib and letrozole in a patient with metastatic HER2-positive and hormone receptor-positive breast cancer: a case report.
Li J; Shui Z; Ouyang Q
Ann Palliat Med; 2021 Sep; 10(9):10124-10129. PubMed ID: 34628933
[TBL] [Abstract][Full Text] [Related]
17. Durable clinical benefit from pyrotinib combined with carboplatin in HER2-positive relapsed breast cancer previously treated with taxanes, anthracyclines, and trastuzumab.
Zhu W; Wu J; Cui M; Zhang L
Ann Palliat Med; 2020 Sep; 9(5):3684-3689. PubMed ID: 33065805
[TBL] [Abstract][Full Text] [Related]
18. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
Wang Y; Jiang T; Qin Z; Jiang J; Wang Q; Yang S; Rivard C; Gao G; Ng TL; Tu MM; Yu H; Ji H; Zhou C; Ren S; Zhang J; Bunn P; Doebele RC; Camidge DR; Hirsch FR
Ann Oncol; 2019 Mar; 30(3):447-455. PubMed ID: 30596880
[TBL] [Abstract][Full Text] [Related]
19. Pyrotinib treatment on HER2-positive gastric cancer cells promotes the released exosomes to enhance endothelial cell progression, which can be counteracted by apatinib.
Gao Z; Song C; Li G; Lin H; Lian X; Zhang N; Cao B
Onco Targets Ther; 2019; 12():2777-2787. PubMed ID: 31114227
[No Abstract] [Full Text] [Related]
20. Pyrotinib shows a potent antitumor effect on HER2-positive esophageal cancer cells by promoting HER2 proteasomal degradation.
Zhao F; Zhu T; Zhao R; Liu J; Ren W
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):191-196. PubMed ID: 38279442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
